A First for Hemorrhoids

Specialty GI play Ventrus Biosciences Inc. is on the road to raise enough in an IPO to get two candidates through Phase III trials. The offering is expected to price on Dec. 13.

The company hopes to sell 2.8 million shares at $6-$7. A $6.50 price would raise $18.2 million and value the company at $41.5 million...